We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Simvastatin therapy in cyclosporine A-induced alveolar bone loss in rats.
- Authors
Nassar, P. O.; Nassar, C. A.; Guimarães, M. R.; Aquino, S. G.; Andia, D. C.; Muscara, M. N.; Spolidorio, D. M. P.; Rossa Jr, C.; Spolidorio, L. C.
- Abstract
Background and Objective: Cyclosporine A treatment is important in the therapy of a number of medical conditions; however, alveolar bone loss is an important negative side-effect of this drug. As such, we evaluated whether concomitant administration of simvastatin would minimize cyclosporine A-associated alveolar bone loss in rats subjected, or not, to experimental periodontal disease. Material and Methods: Groups of 10 rats each were treated with cyclosporine A (10 mg/kg/day), simvastatin (20 mg/kg/day), cyclosporine A and simvastatin concurrently (cyclosporine A/simvastatin) or vehicle for 30 days. Four other groups of 10 rats each received a cotton ligature around the lower first molar and were treated similarly with cyclosporine A, simvastatin, cyclosporine A/simvastatin or vehicle. Calcium (Ca2+), phosphorus and alkaline phosphatase levels were evaluated in serum. Expression levels of interleukin-1β, prostaglandin E2 and inducible nitric oxide synthase were evaluated in the gingivomucosal tissues. Bone volume and numbers of osteoblasts and osteoclasts were also analyzed. Results: Treatment with cyclosporine A in rats, with or without ligature, was associated with bone loss, represented by a lower bone volume and an increase in the number of osteoclasts. Treatment with cyclosporine A was associated with bone resorption, whereas simvastatin treatment improved cyclosporine A-associated alveolar bone loss in all parameters studied. In addition, simvastatin, in the presence of inflammation, can act as an anti-inflammatory agent. Conclusion: This study shows that simvastatin therapy leads to a reversal of the cyclosporine A-induced bone loss, which may be mediated by downregulation of interleukin-1β and prostaglandin E2 production.
- Subjects
CYCLOSPORINE; BONE diseases; SERUM; PHOSPHATASES; ANTI-inflammatory agents
- Publication
Journal of Periodontal Research, 2009, Vol 44, Issue 4, p479
- ISSN
0022-3484
- Publication type
Article
- DOI
10.1111/j.1600-0765.2008.01143.x